Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T23:30:34.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding pembrolizumab following TACE for primary liver carcinoma, while adding a new version revision and a reference to the study's location.
    Difference
    38%
    Check dated 2025-04-17T10:53:39.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The page has updated its version from v2.14.3 to v2.14.4 and removed a date of March 25, 2025, while adding new dates of February 3, 2025, and March 6, 2025.
    Difference
    0.4%
    Check dated 2025-04-10T05:33:14.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The page has updated its date references, adding new dates in March 2025 while removing older dates from January and February 2025.
    Difference
    0.7%
    Check dated 2025-03-12T05:16:11.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-25T19:08:32.000Z thumbnail image
  9. Check
    97 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-11T07:35:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.